1. Home
  2. > Pharmaceutical Market Trends
Pharma R&D Outsourcing Market - Global Outlook & Forecast 2022-2027

Pharma R&D Outsourcing Market - Global Outlook & Forecast 2022-2027

  • September 2022
  • 357 pages
  • ID: 6320993
  • Format: PDF
  • Arizton


Table of Contents

The global pharma R&D outsourcing market is expected to grow at a CAGR of 9.56% during 2022-2027.


In a world of exponentially growing information, increasingly sophisticated technology, and an unstable economic environment, pharmaceutical corporations are increasingly outsourcing research efforts to academia and private contract research organizations (CROs). The pharmaceutical R&D outsourcing market is expected to grow as pharmaceutical and biotechnology companies spend more on outsourced services. Outsourced R&D activities span basic research through late-stage development, including genetic engineering, target identification, target validation, assay creation, hit discovery and lead optimization (hit candidates-as-a-service), safety and efficacy assessments in animal studies, and human clinical trials.

Paradigm Shift Towards Virtual Clinical Trials

• Virtual clinical trials or decentralized clinical trials can bring significant digital changes to clinical research methods and enhance the patient-centric ecosystem. These solutions include countless benefits such as technology, advanced applications, electronic devices, online social engagement platforms, artificial intelligence (AI), robotic process automation, and machine learning (ML).
• Patient recruitment is the most prominent cause of clinical delay, followed by significant patient absenteeism. Approximately 30% of phase 3 study discontinuances are said to be due to difficulty recruiting patients. These delays can cost pharmaceutical companies/sponsors up to USD 8 million daily. However, a complete digital or cross model of patient enrolment is employed in decentralized clinical trials. This helps reach the recruitment target easily and rapidly, making the entire process easy, and engaging.

The Emergence of Artificial intelligence (AI) in Drug Discovery & Development

• Artificial intelligence (AI) is used in numerous areas across the world. In healthcare, especially in the pharmaceutical industry, AI is making a notable change as it has varied uses in drug discovery & development, clinical trials, and pharmaceutical productivity. The life cycle of a new drug from a lab to a store is a chain of many complex events that take time and development. Such difficult circumstances can be minimized with the help of AI, and the target can be achieved in a short time.
• Many pharmaceutical companies implement innovative technologies such as AI and machine learning to achieve high-quality results in a short amount of time. In pharmaceutical product development, AI can manage the drug designing, decision making, and therapy determination for patients with personalized medicines; the generated clinical data can be stored for future drug development.
• Global key players from the pharma and biotech industry, such as Eli Lilly Amgen, Merck, LEO, AstraZeneca, Bayer, Novartis, J&J, and BASF, are now a part of machine learning for pharmaceutical discovery.

Increasing Collaboration and partnership among CROs and Stakeholders of the Pharmaceutical Ecosystem

• New models are emerging, and the first innovation comes from the Clinical Research Organization (CRO). CROs establish early chemical / biological entry points for the disease, approach potential interested companies, and collaborate on integrated drug discovery projects that they have identified. Strategic partnerships have long been an essential feature of the pharmaceutical industry. Numerous in-licenses, out-licenses, joint research, and joint development agreements exist between biopharmaceutical companies and academic research institutes.
• In recent years, several significant outsourcing partnerships were done, such as the UK-based AstraZeneca partnering with academic organizations, the Cambridge University, focusing on drug development. It partnered with the University of Texas MD Anderson Cancer Center in the United States to develop immunotherapy.

Some of the examples of significant strategic partnerships of outsourcing are:

a) Allied Minds & Bristol-Myers Squibb
b) GSK & University of Leicester
c) Actelion Pharmaceuticals & Enamine


The pharma R&D outsourcing market is segmented on the product, stage of development, size of companies, therapy areas, and geography.

Insights by Product

Among all products, the small molecules segment reported a significant pharma R&D outsourcing market share. The small molecules segment is estimated to be higher because small molecules are likely to play a crucial part in easing the burden of chronic disease. This diverse group of small chemical compounds offers many benefits for scientists and researchers:

a) They have a wide-ranging use.
b) They are comparatively low in cost.
c) They allow for easy administration, including an oral route of administration.
d) They can pass within cell membranes to achieve their targets due to their small size.
e) They provide consistent results.

Pharmaceutical companies planning small molecule clinical studies need to work with the appropriate contract research organization (CRO) to conduct valuable research using reliable data. The food and Drug Administration (FDA) approved 50 novel drugs in 2021. 36 are small molecules which is 72% of the total approval of pharmaceutical drugs by the FDA.

Segmentation by Product Type

• Small Molecules
• Biologics

Insights by Stage of development

a) Among stages of development, the clinical segment reported a major share of around 64.13% in 2021. The clinical segment is estimated to be higher because, according to World Health Organization (WHO), approximately 47,689 clinical trials are in Phase I. The high number of clinical trials in phase 1 is highly outsourced. In outsourcing well-established data about patient recruitment, activities of clinical trials related to phase 1 and other procedures such as analysis and documentation are the easy thing done in the phase.
b) Phase 1 clinical trials required more than USD 30 million in capital investment. Compounds in oncology, respiratory diseases, and other therapeutic areas require a lot of money. Around 70% of drugs move from Phase I to the next phase states by US FDA.
c) Phase II can last for several years; as per the WHO, around 88,530 compounds in phase 2 clinical trials till 2022. As per US FDA, approximately 33% of new drugs are moved from phase II to the next.
d) The number of subjects usually ranges from hundreds to about 3,000. If the FDA agrees that the study results are positive, the FDA will approve the experimental drug or equipment. As per the WHO, around 68,999 drugs came to phase III till 2022. In this phase, doctors, physicians, or professionals do not know whether the treatment is better, so random participants are picked up to get the approval for new treatment and sent into the next phase. This procedure is often done in many places across the region/world at the same time to analyze the efficacy of drugs in different geography and demography.

Segmentation by Stage of Development

• Clinical
• Non-Clinical

Insights by Size of Company

a) Among the size of the company, the small & mid-sized companies segment reported a major share of around 57.54% in 2021. The small & mid-sized companies market segment is estimated to be higher because, in 2019, the emerging therapeutic companies (ETC) were responsible for 73% (5,067 of 6,984) of global industrial, and pharmaceutical projects at all clinical stages, either alone or in collaboration with partners, with the rest being carried out by large companies.
b) SMEs will account for 71%, 76%, 68%, and 62% of Phase I, II, III, and new drug applications, respectively, compared to large companies. 45% of all clinical ETC pipeline projects are carried out in collaboration with other partners. Oncology is the main disease focus of these SME clinical projects.
c) In 2018, the Market researcher identified that 74 small pharmaceutical companies have total sales of $159 billion and 446 pharmaceuticals drugs in their R&D pipeline, 9 medium-sized companies with sales of $50 billion and 181 products, and sales of $139 billion in the R& D pipeline.
d) A 2017 BIO industry analysis shows that small biotechnology companies are responsible for 70% of all bio pharmacy clinical trials worldwide, representing 6,679 programs, 43% of which partner with other companies. It was carried out. Large companies conducted the remaining 30% of these clinical trials.

Segmentation by Company Size

• Small & Mid-Sized Companies
• Large Companies

Insights by Therapy Areas

a) Among therapy areas, the oncology segment reported a major share of around 30.71% in 2021. The oncology segments are estimated to be higher because there are 19.3 million new cancer instances and approximately 10 million fatalities worldwide in 2020, accounting for nearly one out of every six deaths as per Globocan 2020 report.
b) Oncology is one of the most dominant therapy areas for industry and non-industry-sponsored clinical trials. The rising prevalence of cancer conditions significantly contributed to oncology therapeutic area clinical trials. Changing the paradigm for testing cancer treatment in the world increased the global efforts toward generating evidence for oncology clinical trials.
c) In 2019 only around 30 FDA approvals were registered for chemotherapeutic drugs. In the US, about 361,628 clinical trials have been reported only for cancer in the past 20 years. Cancer clinical trial drug development activities increased significantly, leading to increased clinical trial volume.
d) Global spending on anticancer medications climbed by 14.3% in 2020, reaching $164 billion. Spending is expected to reach $269 billion by 2025. The high prices of novel anticancer medicines drive much of this growth. The direct and indirect expenses of oncological treatments severely affect patients’ treatment success and financial well-being worldwide.
e) In the US, around 361,628 clinical trials registered only for cancer in the past 20 years. Cancer clinical trial drug development activities increased significantly, leading to increased clinical trial volume.

Segmentation by Therapy Area

• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Musculoskeletal Disorders
• Central Nervous System Disorders
• Gastrointestinal Disorders
• Other Therapy Areas


The North America region reported a significant share of around 36.23% in 2021. The North America region is estimated to be higher because considerable investment by companies in R&D to strengthen the pipeline for chronic diseases is projected to boost the launch of novel therapeutics in North America. North America witnesses prominent start-up CROs working in the pharmaceutical R&D outsourcing market. The region also saw collaborations and partnerships among the pharmaceutical ecosystem’s stakeholders.

Segmentation by Geography

• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o China
o Japan
o India
o Australia
o South Korea
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o Turkey

Vendors in the pharma R&D outsourcing market compete based on the wide range of services offered, quality, and scale-up development of pharmaceuticals. The market is so competitive that vendors aim to implement different strategies to maintain their competitive advantage over other vendors. The market players focus on acquisitions, partnerships, diversifying their outsourcing services, and strengthening their distribution networks to increase their market share. There are around 33 vendors in the pharmaceutical R&D outsourcing market, including key players and other prominent players.

Key Vendors
• Charles River Laboratories
• Labcorp Drug Development
• Medpace
• Parexel International Corporation
• Syneos Health
• Thermo Fisher Scientific
• Wuxi AppTec
• Lonza
• Boehringer Ingelheim
• Samsung Biologics

Other Prominent Vendors
• AbbVie
• Advanced Clinical
• BioAnalytix
• Asymchem
• Alcami
• Bavarian Nordic
• Catalent
• Curia Global
• ChemPartner
• Criterium
• Cromos Pharma
• Evotec
• Jubilant HollisterStier
• KBI Biopharma
• KCR S.A.
• Kemwell Biopharma
• Mesned Pharma Consult Center
• Midas Pharma
• Medelis
• Merck KGaA
• OCT Clinical
• Pharmaceutics International
• ProTrials Research
• Singota Solutions
• Sofpromed
• Sanofi
• Taros chemicals
• Veristat
• Worldwide Clinical Trials
• WuXi Biologics
• Wacker Biotech B.V

1. How big is the pharmaceutical R&D outsourcing market?
2. What is the growth rate of the global pharmaceutical R&D outsourcing market?
3. Who are the key players in the global pharma R&D outsourcing market?
4. Which geographical region leads in the pharma R&D outsourcing market?
5. What are the growth factors in the global pharmaceutical R&D outsourcing market?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global miRNA Tools and Services Market Size, Share & Industry Trends Analysis Report By Technology, By End User, By Product & Services, By Regional Outlook and Forecast, 2022 - 2028

  • $ 3600
  • October 2022
  • 218 pages

The Global miRNA Tools and Services Market size is expected to reach $939.8 million by 2028, rising at a market growth of 17.8% CAGR during the forecast period. miRNA is a non-coding and small gene that ...

  • World
  • North America
  • Drug Development
  • Pharmaceutical
  • Industry analysis
  • Chronic Disease Prevalence
  • Cancer Incidence


Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on